AU775373B2
(en)
|
1999-10-01 |
2004-07-29 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7097840B2
(en)
*
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
AR030612A1
(es)
*
|
2000-09-12 |
2003-08-27 |
Smithkline Beecham Corp |
Procedimiento e intermedios
|
US20020156274A1
(en)
*
|
2001-03-16 |
2002-10-24 |
Terfloth Gerald J. |
Process for preparing maytansinol
|
US20090123470A1
(en)
*
|
2001-03-26 |
2009-05-14 |
The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. |
Antibodies Against Cancer
|
AUPR395801A0
(en)
*
|
2001-03-26 |
2001-04-26 |
Austin Research Institute, The |
Antibodies against cancer
|
US7582299B2
(en)
*
|
2001-04-26 |
2009-09-01 |
Biogen Idec Ma Inc. |
Cripto-specific antibodies
|
CN100352501C
(zh)
*
|
2001-04-26 |
2007-12-05 |
比奥根艾迪克Ma公司 |
Cripto阻断抗体及其用途
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
US6441163B1
(en)
*
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
US7045605B2
(en)
|
2001-06-01 |
2006-05-16 |
Cornell Research Foundation, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
CN1278739C
(zh)
*
|
2001-06-08 |
2006-10-11 |
中国人民解放军第四军医大学 |
包含抗人精浆蛋白单链抗体/人羧肽酶a融合蛋白及前体药物的药盒
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20090297531A1
(en)
*
|
2001-06-20 |
2009-12-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
ES2372321T3
(es)
*
|
2001-06-20 |
2012-01-18 |
Genentech, Inc. |
Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón.
|
DE10215336A1
(de)
*
|
2002-03-28 |
2003-10-23 |
Schering Ag |
N-Methyl-Homocysteine und ihre Verwendung sowie Verfahren zu ihrer Herstellung
|
JP2005525423A
(ja)
*
|
2002-05-13 |
2005-08-25 |
スミスクライン・ビーチャム・コーポレイション |
メイタンシノールの調製方法
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
EP1536814A4
(en)
*
|
2002-07-03 |
2006-02-15 |
Immunogen Inc |
ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US7432088B2
(en)
|
2003-05-08 |
2008-10-07 |
Immunogen Inc. |
Methods for the production of ansamitocins
|
KR101424624B1
(ko)
*
|
2003-05-14 |
2014-07-31 |
이뮤노젠 아이엔씨 |
약물 콘쥬게이트 조성물
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
US7276497B2
(en)
*
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
PT3524611T
(pt)
*
|
2003-05-20 |
2021-04-01 |
Immunogen Inc |
Agentes citotóxicos melhorados compreendendo novos maitansinóides
|
MXPA05014030A
(es)
*
|
2003-06-27 |
2007-02-13 |
Diadexus Inc |
Composiciones de anticuerpo pro 104 y metodos de uso.
|
US7834155B2
(en)
|
2003-07-21 |
2010-11-16 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
US20050123549A1
(en)
*
|
2003-07-21 |
2005-06-09 |
Immunogen Inc. |
CA6 antigen-specific cytotoxic conjugate and methods of using the same
|
WO2005018545A2
(en)
*
|
2003-08-14 |
2005-03-03 |
Merck & Co., Inc. |
Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
|
US6890962B1
(en)
*
|
2003-11-25 |
2005-05-10 |
Chevron U.S.A. Inc. |
Gas-to-liquid CO2 reduction by use of H2 as a fuel
|
EP2286844A3
(en)
*
|
2004-06-01 |
2012-08-22 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
CA2486285C
(en)
*
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
AU2005306701A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Merck & Co., Inc. |
Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of Alzheimer's disease
|
CA2587256A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Merck & Co., Inc. |
Macrocyclic aminopyridyl beta-secretase inhibitors for the treatment of alzheimer's disease
|
ES2408704T3
(es)
|
2005-01-05 |
2013-06-21 |
Biogen Idec Ma Inc. |
Moléculas de unión a Cripto
|
US7301019B2
(en)
*
|
2005-01-21 |
2007-11-27 |
Immunogen, Inc. |
Method for the preparation of maytansinoid esters
|
EP1853322B1
(en)
*
|
2005-02-11 |
2014-06-25 |
ImmunoGen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
CA2600418A1
(en)
*
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Stabilized aptamers to psma and their use as prostate cancer therapeutics
|
EP1868647A4
(en)
|
2005-03-24 |
2009-04-01 |
Millennium Pharm Inc |
OV064 BINDING ANTIBODIES AND METHOD FOR THEIR USE
|
KR101566393B1
(ko)
*
|
2005-08-03 |
2015-11-05 |
이뮤노젠 아이엔씨 |
면역접합체 제형
|
CA2617953C
(en)
*
|
2005-08-09 |
2013-12-17 |
Millennium Pharmaceuticals, Inc. |
Method of acylating maytansinol with chiral amino acids
|
AU2006283726C1
(en)
*
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
PL1945647T3
(pl)
*
|
2005-11-08 |
2012-04-30 |
Immunogen Inc |
Procesy wytwarzania maytansinolu
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
ES2673822T3
(es)
*
|
2006-07-18 |
2018-06-25 |
Sanofi |
Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
CA2670471A1
(en)
|
2006-11-22 |
2008-06-05 |
Adnexus, A Bristol-Myers Squibb R&D Company (A Delaware Corporation) |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
MX2009009912A
(es)
|
2007-03-27 |
2010-01-18 |
Sea Lane Biotechnologies Llc |
Constructos y colecciones que comprenden secuencias de cadena ligera sustitutas de anticuerpos.
|
US20090011060A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Peter Koepke |
Campsiandra angustifolia extract and methods of extracting and using such extract
|
US20090017140A1
(en)
*
|
2007-07-09 |
2009-01-15 |
Peter Koepke |
Maytenus abenfolia extract and methods of extracting and using such extract
|
DK2474557T3
(da)
|
2007-07-16 |
2014-11-10 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
US20090035395A1
(en)
*
|
2007-08-01 |
2009-02-05 |
Peter Koepke |
Spondias mombin l. extract and methods of extracting and using such extract
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
NO2195023T3
(da)
|
2007-08-29 |
2018-08-04 |
|
|
US7879369B2
(en)
*
|
2007-09-18 |
2011-02-01 |
Selvamedica, Llc |
Combretum laurifolium Mart. extract and methods of extracting and using such extract
|
EP2050764A1
(en)
*
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Novel polyvalent bispecific antibody format and uses thereof
|
JP5990365B2
(ja)
|
2007-12-26 |
2016-09-14 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138を標的とする剤及びその使用
|
WO2009080831A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
JP5817034B2
(ja)
*
|
2007-12-26 |
2015-11-18 |
バイオテスト・アクチエンゲゼルシヤフト |
Cd138を標的とする免疫複合体及びその使用
|
MX2010007101A
(es)
*
|
2007-12-26 |
2011-07-01 |
Biotest Ag |
Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138.
|
DK2657253T3
(da)
|
2008-01-31 |
2017-10-09 |
Genentech Inc |
Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
|
EP2644204B1
(en)
|
2008-03-18 |
2017-04-19 |
Genentech, Inc. |
Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab
|
KR20220035504A
(ko)
|
2008-04-30 |
2022-03-22 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
EP2799448A1
(en)
|
2008-05-22 |
2014-11-05 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
JP5611210B2
(ja)
|
2008-09-07 |
2014-10-22 |
グリコネックス インコーポレイテッド |
抗拡張i型スフィンゴ糖脂質抗体、その誘導体および使用
|
US8466260B2
(en)
|
2009-04-01 |
2013-06-18 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
WO2010126979A1
(en)
|
2009-04-29 |
2010-11-04 |
Bio-Rad Laboratories, Inc. |
Purification of immunoconjugates
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
KR101537840B1
(ko)
|
2009-05-13 |
2015-07-22 |
젠자임 코포레이션 |
항-인간 cd52 면역글루불린
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
SG10201810743WA
(en)
|
2009-06-03 |
2018-12-28 |
Immunogen Inc |
Conjugation methods
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
AR078471A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
|
TW201116297A
(en)
|
2009-10-02 |
2011-05-16 |
Sanofi Aventis |
Antibodies that specifically bind to the EphA2 receptor
|
EP2486023A4
(en)
|
2009-10-06 |
2014-05-07 |
Immunogen Inc |
EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
|
KR20120093932A
(ko)
|
2009-10-10 |
2012-08-23 |
일레븐 바이오테라피틱스, 아이엔씨. |
Il-17 패밀리 사이토카인 조성물들 및 용도들
|
MX366890B
(es)
|
2009-10-23 |
2019-07-30 |
Millennium Pharm Inc |
Moléculas de anticuerpo anti - gcc y composiciones y métodos relacionados.
|
TW201129380A
(en)
|
2009-12-04 |
2011-09-01 |
Genentech Inc |
Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
CN103037900B
(zh)
|
2010-02-24 |
2016-04-06 |
伊缪诺金公司 |
叶酸受体1抗体与免疫缀合物以及其用途
|
NZ701539A
(en)
|
2010-03-04 |
2015-04-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
AR080513A1
(es)
|
2010-03-12 |
2012-04-11 |
Inmunogen Inc |
Moleculas de union cd37 y sus inmunoconjugados
|
ME02670B
(me)
|
2010-03-26 |
2017-06-20 |
Memorial Sloan Kettering Cancer Center |
Antitela za MUC16 i metode za njihovu primenu
|
WO2011133555A2
(en)
|
2010-04-20 |
2011-10-27 |
The Research Foundation Of State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (mmp)-mediated cell migration
|
CN103052649B
(zh)
|
2010-07-29 |
2015-12-16 |
Xencor公司 |
具有修改的等电点的抗体
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
EP2632490A4
(en)
|
2010-10-29 |
2014-10-22 |
Immunogen Inc |
NOVEL MOLECULES BINDING TO THE EGF RECEPTOR AND IMMUNOCONJUGATES THEREOF
|
CN105399831A
(zh)
|
2010-10-29 |
2016-03-16 |
伊缪诺金公司 |
非拮抗性egfr结合分子及其免疫偶联物
|
EP3708586A1
(en)
|
2010-10-29 |
2020-09-16 |
Perseus Proteomics Inc. |
Anti-cdh3 antibody having high internalization capacity
|
ES2544608T3
(es)
|
2010-11-17 |
2015-09-02 |
Genentech, Inc. |
Conjugados de anticuerpo y de alaninil-maitansinol
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
EP2686014A1
(en)
|
2011-03-16 |
2014-01-22 |
Sanofi |
Uses of a dual v region antibody-like protein
|
SI2691155T1
(sl)
|
2011-03-29 |
2019-03-29 |
Immunogen, Inc. |
Priprava majtanzinoidnih konjugatov protiteles v postopku z enim korakom
|
SG193997A1
(en)
|
2011-03-29 |
2013-11-29 |
Immunogen Inc |
Process for manufacturing conjugates of improved homogeneity
|
ME03440B
(me)
|
2011-05-21 |
2020-01-20 |
Macrogenics Inc |
Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
|
EP3228325A1
(en)
|
2011-06-10 |
2017-10-11 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
CA2836927A1
(en)
|
2011-06-21 |
2012-12-27 |
Immunogen, Inc. |
Novel maytansinoid derivatives with peptide linker and conjugates thereof
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
EP2758437B1
(en)
|
2011-09-22 |
2020-06-03 |
Amgen Inc. |
Cd27l antigen binding proteins
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2766392B1
(en)
|
2011-10-10 |
2019-07-17 |
Xencor, Inc. |
A method for purifying antibodies
|
EP2794010A4
(en)
|
2011-11-21 |
2015-10-21 |
Immunogen Inc |
METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE
|
MX358680B
(es)
|
2011-12-08 |
2018-08-31 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a cd138.
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
CA2862292C
(en)
|
2012-01-20 |
2019-10-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CN104220595A
(zh)
|
2012-04-04 |
2014-12-17 |
株式会社英仙蛋白质科学 |
抗cdh3(p-钙粘着蛋白)抗体的药剂偶联物
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
CA2867824A1
(en)
|
2012-05-01 |
2013-11-07 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
UY34813A
(es)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
Proteínas de unión a antígeno dirigidas contra el receptor st2
|
US9738696B2
(en)
|
2012-08-09 |
2017-08-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
|
SG10201702737TA
(en)
|
2012-10-04 |
2017-05-30 |
Immunogen Inc |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
SI3199552T1
(sl)
|
2012-11-20 |
2020-06-30 |
Sanofi |
Protitelesa proti-CEACAM5 in njihove uporabe
|
AU2012395148B2
(en)
|
2012-11-24 |
2016-10-27 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
US10226535B2
(en)
|
2012-12-10 |
2019-03-12 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
CA2892863C
(en)
|
2012-12-10 |
2022-03-15 |
Mersana Therapeutics, Inc. |
Polymeric scaffold based on phf for targeted drug delivery
|
WO2014093640A1
(en)
|
2012-12-12 |
2014-06-19 |
Mersana Therapeutics,Inc. |
Hydroxy-polmer-drug-protein conjugates
|
CN103333246B
(zh)
|
2012-12-21 |
2015-09-16 |
百奥泰生物科技(广州)有限公司 |
一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
|
CN103288957B
(zh)
|
2012-12-21 |
2015-01-28 |
百奥泰生物科技(广州)有限公司 |
一种抑制肿瘤生长的抗体药物衍生物及其制备方法和用途
|
CN104650113A
(zh)
|
2012-12-21 |
2015-05-27 |
百奥泰生物科技(广州)有限公司 |
类美登素衍生物及其制备方法和用途
|
CN103254213B
(zh)
|
2012-12-21 |
2015-02-25 |
百奥泰生物科技(广州)有限公司 |
类美登素酯的制备方法及用于所述方法的组合物
|
EA201690004A1
(ru)
|
2012-12-27 |
2016-07-29 |
Санофи |
Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
SG11201506358PA
(en)
|
2013-02-15 |
2015-09-29 |
Perseus Proteomics Inc |
Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
PL3587448T3
(pl)
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
DK2970486T3
(da)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
Modulering af t-celler med bispecifikke antistoffer og fc-fusioner
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014183068A2
(en)
|
2013-05-10 |
2014-11-13 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Treatment of pulmonary and other conditions
|
EA201592285A1
(ru)
|
2013-05-30 |
2016-05-31 |
Байоджен Ма Инк. |
Антигенсвязывающие белки к рецептору онкостатина м
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
CN106164093A
(zh)
|
2013-10-08 |
2016-11-23 |
伊缪诺金公司 |
抗folr1免疫偶联物给药方案
|
EP3054991B1
(en)
|
2013-10-11 |
2019-04-03 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
AU2014333563B9
(en)
|
2013-10-11 |
2020-04-02 |
Oxford Biotherapeutics Ltd |
Conjugated antibodies against LY75 for the treatment of cancer
|
JP6427564B2
(ja)
|
2013-10-11 |
2018-11-21 |
アサナ・バイオサイエンシズ,リミテッド・ライアビリティ・カンパニー |
タンパク質−ポリマー−薬物共役体
|
EA201691214A1
(ru)
|
2013-12-13 |
2016-12-30 |
Дженентек, Инк. |
Антитела к cd33 и иммуноконъюгаты
|
EP3082875B1
(en)
|
2013-12-16 |
2020-11-25 |
Genentech, Inc. |
Peptidomimetic compounds and antibody-drug conjugates thereof
|
TWI541022B
(zh)
|
2013-12-18 |
2016-07-11 |
應克隆公司 |
針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法
|
US9943606B2
(en)
|
2014-01-15 |
2018-04-17 |
Rutgers, The State University Of New Jersey |
Dendritic polypeptide-based nanocarriers for the delivery of therapeutic agents
|
RU2016130349A
(ru)
|
2014-01-24 |
2018-03-01 |
Дженентек, Инк. |
Способы применения антител против steap1 и иммуноконъюгатов
|
MX2016010505A
(es)
|
2014-02-14 |
2017-04-13 |
S Chi Andrew |
Metodos mejorados para el tratamiento de canceres vascularizantes.
|
ES2960619T3
(es)
|
2014-02-28 |
2024-03-05 |
Hangzhou Dac Biotech Co Ltd |
Enlazadores cargados y sus usos para la conjugación
|
EP3116486B1
(en)
|
2014-03-14 |
2019-12-04 |
Daniel J. Capon |
Hybrid immunoglobulin containing non-peptidyl linkage
|
ME03666B
(me)
|
2014-03-28 |
2020-10-20 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
CN106414499A
(zh)
|
2014-05-22 |
2017-02-15 |
基因泰克公司 |
抗gpc3抗体和免疫偶联物
|
US20160060360A1
(en)
|
2014-07-24 |
2016-03-03 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
US20170260261A1
(en)
|
2014-08-28 |
2017-09-14 |
Bioatla, Llc |
Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
|
MA42561A
(fr)
|
2014-09-02 |
2018-04-25 |
Immunogen Inc |
Procédés de formulation de compositions de conjugués anticorps-médicament
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
CA2958479A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
CN105585579A
(zh)
*
|
2014-10-24 |
2016-05-18 |
南京联宁生物制药有限公司 |
一种化合物及其制备方法以及美登素dm1的制备方法
|
AU2015347015B2
(en)
|
2014-11-14 |
2019-02-14 |
Novartis Ag |
Antibody drug conjugates
|
US10413615B2
(en)
|
2014-11-19 |
2019-09-17 |
Immunogen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
KR20170084326A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 종양 항원과 결합하는 이종이량체 항체
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
SG10202008302XA
(en)
|
2014-12-04 |
2020-10-29 |
Celgene Corp |
Biomolecule conjugates
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
CA2978182A1
(en)
|
2015-03-17 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Amino acid acylation reagents and methods of using the same
|
WO2016149485A1
(en)
|
2015-03-17 |
2016-09-22 |
The Regents Of The University Of California |
Novel chemoimmunotherapy for epithelial cancer
|
TW201711702A
(zh)
|
2015-06-04 |
2017-04-01 |
應克隆公司 |
使用針對纖維母細胞生長因子受體3(fgfr3)之化合物的療法
|
JP6979877B2
(ja)
|
2015-06-08 |
2021-12-15 |
デビオファーム インターナショナル, エス. アー. |
抗cd37イムノコンジュゲートおよび抗cd20抗体の組み合わせ
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
WO2017025458A1
(en)
|
2015-08-07 |
2017-02-16 |
Gamamabs Pharma |
Antibodies, antibody drug conjugates and methods of use
|
US10172875B2
(en)
|
2015-09-17 |
2019-01-08 |
Immunogen, Inc. |
Therapeutic combinations comprising anti-FOLR1 immunoconjugates
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
EP3411077A1
(en)
|
2016-02-05 |
2018-12-12 |
ImmunoGen, Inc. |
Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
|
CN109563164A
(zh)
|
2016-04-15 |
2019-04-02 |
生物蛋白有限公司 |
抗axl抗体、抗体片段和它们的免疫缀合物以及其用途
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
HRP20221298T1
(hr)
|
2016-05-13 |
2022-12-23 |
Bioatla, Inc. |
Anti-ror2 protutijela, fragmenti protutijela, njihovi imunokonjugati i njihove uporabe
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
EP4257613A3
(en)
|
2016-06-14 |
2023-12-13 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
EP3474901A1
(en)
|
2016-06-27 |
2019-05-01 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
PE20191034A1
(es)
|
2016-10-14 |
2019-08-05 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
|
EP3535297B1
(en)
|
2016-11-02 |
2022-08-10 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
US20210308277A1
(en)
|
2016-11-14 |
2021-10-07 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
|
KR102221364B1
(ko)
|
2016-11-21 |
2021-03-04 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
CN111315414A
(zh)
|
2017-06-22 |
2020-06-19 |
梅尔莎纳医疗公司 |
产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
WO2019040474A1
(en)
|
2017-08-22 |
2019-02-28 |
Purdue Research Foundation |
THERAPEUTIC AND RADIOIMAGING CONJUGATES BASED ON FBSA TARGETING POSITIVE CANCERS FOR CARBONIC ANHYDRASE
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
AU2018390418B2
(en)
|
2017-12-19 |
2023-12-21 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
WO2019164891A1
(en)
|
2018-02-21 |
2019-08-29 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
WO2019212357A1
(en)
|
2018-05-04 |
2019-11-07 |
Tagworks Pharmaceuticals B.V. |
Compounds comprising a linker for increasing transcyclooctene stability
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
MX2020012755A
(es)
|
2018-05-30 |
2021-02-26 |
Debiopharm Int Sa |
Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37).
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
BR112020026724A2
(pt)
|
2018-07-02 |
2021-03-30 |
Amgen Inc. |
Proteína de ligação ao antígeno anti-steap1
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|
AU2019355971A1
(en)
|
2018-10-03 |
2021-05-06 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
JP2022513400A
(ja)
|
2018-10-29 |
2022-02-07 |
メルサナ セラピューティクス インコーポレイテッド |
ペプチド含有リンカーを有するシステイン操作抗体-薬物コンジュゲート
|
EP3920972A1
(en)
|
2019-02-07 |
2021-12-15 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
EP3693023A1
(en)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
CA3132185A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
EP4219509A1
(en)
|
2019-03-01 |
2023-08-02 |
Celgene Corporation |
Preparation of maytansinol
|
PT3956332T
(pt)
|
2019-04-18 |
2023-04-24 |
Indena Spa |
Processo diasterosselectivo para a preparação de ésteres de maitansinoides contendo tiol ou dissulfeto e seus intermediários
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
JP2022537543A
(ja)
|
2019-06-17 |
2022-08-26 |
タグワークス ファーマシューティカルス ビー.ブイ. |
高速で且つ効率的なクリック放出の為の化合物
|
EP4045090A1
(en)
|
2019-10-18 |
2022-08-24 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
JPWO2021107133A1
(da)
|
2019-11-29 |
2021-06-03 |
|
|
CA3163833A1
(en)
|
2020-01-09 |
2021-07-15 |
Timothy B. Lowinger |
Site specific antibody-drug conjugates with peptide-containing linkers
|
CA3181005A1
(en)
|
2020-04-24 |
2021-10-28 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
|
US20230087871A1
(en)
|
2020-04-24 |
2023-03-23 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
|
IL297207A
(en)
|
2020-04-24 |
2022-12-01 |
Sanofi Sa |
Combinations against tumors containing conjugates of antibodies to trifluridine, ceacam5 and tipiracil
|
CN115427083A
(zh)
|
2020-04-24 |
2022-12-02 |
赛诺菲 |
含有抗ceacam5抗体缀合物和西妥昔单抗的抗肿瘤组合
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
EP4178624A2
(en)
|
2020-07-07 |
2023-05-17 |
Bionecure Therapeutics, Inc. |
Maytansinoids as adc payloads and their use for the treatment of cancer
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CN118339280A
(zh)
|
2021-09-06 |
2024-07-12 |
维拉克萨生物技术有限责任公司 |
用于真核生物中遗传密码子扩展的新型氨酰tRNA合成酶变体
|
WO2023079057A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
WO2023094525A1
(en)
|
2021-11-25 |
2023-06-01 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
CA3241254A1
(en)
|
2021-12-02 |
2023-06-08 |
Sanofi |
Ceacam5 adc-anti-pd1/pd-l1 combination therapy
|
WO2023099683A1
(en)
|
2021-12-02 |
2023-06-08 |
Sanofi |
Cea assay for patient selection in cancer therapy
|
CA3239713A1
(en)
|
2021-12-08 |
2023-06-15 |
Edward A. LEMKE |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
EP4314031B1
(en)
|
2022-02-15 |
2024-03-13 |
Tagworks Pharmaceuticals B.V. |
Masked il12 protein
|
WO2024013723A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody drug conjugates that bind cdcp1 and uses thereof
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|